miR-641 is a target of LINC00173 in HCC cells. (A) StarBase was used to predict potential binding sites between LINC00173 and miR-641. (B) RT-qPCR analysis of relative miR-641 expression in Huh7/DDP and Hep3B/DDP cells transfected with NC or miR-641 mimics. Luciferase activity of LINC00173-wt or LINC00173-mut in (C) Huh7/DDP and (D) Hep3B/DDP cells transfected with NC or miR-641 mimics. (E) RT-qPCR analysis of relative miR-641 expression in Huh7/DDP and Hep3B/DDP cells transfected with shLINC00173, shNC, pcDNA3.1/LINC00173 and pcDNA3.1. Relative miR-641 expression in (F) HCC tissues and (G) DDP-resistant HCC tissues was determined by RT-qPCR. (H) Pearson's correlation analysis revealed a negative correlation between miR-641 and LINC00173 expression in HCC tissues. *P<0.05. miR, microRNA; HCC, hepatocellular carcinoma; RT-qPCR, reverse transcription-quantitative PCR; DDP, cisplatin; wt, wild-type; mut, mutant; NC, negative control; sh, short hairpin.